| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
Purity: ≥98%
TMP195 (TMP-195) is a first-in-class and selective inhibitor of class IIa histone deacetylase (HDAC) with anticancer and immunomodulatory effects. Its IC50 value for HDAC inhibition is 300 nM. By modifying macrophage phenotypes, in vivo TMP195 treatment modifies the tumor microenvironment and lowers tumor burden and pulmonary metastases. Within tumors, TMP195 promotes the recruitment and differentiation of highly stimulatory and phagocytic macrophages. Moreover, in this model, the combination of TMP195 and chemotherapy regimens or T-cell checkpoint blockade greatly improves the durability of tumor reduction. These findings present class IIa HDAC inhibition as a way to improve cancer therapy by utilizing macrophages' anti-tumor properties. In the supernatants of cultures where monocytes are differentiated into macrophages, TMP195 prevents the buildup of CCL2 protein. Comparing the vehicle group to the TMP195 group, the monocytes secrete significantly more CCL1 protein. TMP195 down- or up-regulates CCL2 and CCL1, respectively, according to the transcriptional profiling data from the PHA-stimulated PBMC experiments.
| Targets |
HDAC9 ( IC50 = 9 nM ); HDAC7 ( IC50 = 46 nM ); HDAC5 ( IC50 = 106 nM ); HDAC4 ( IC50 = 111 nM ); HDAC8 ( IC50 = 11700 nM ); HDAC6 ( IC50 = 47800 nM )
|
|
|---|---|---|
| ln Vitro |
|
|
| ln Vivo |
|
|
| Enzyme Assay |
The labeled recombinant HDAC7 catalytic domain (amino acids 483-903) is applied to an arrayed library of 3,868 immobilized 20-mer peptides using DyLight 650. Using an automated TECAN HS4 microarray processing station, arrays are performed. First, blocking buffer is incubated for 30 minutes at 30°C. Next, saline containing 50 mM Tris Base and 0.1% Tween-20 (pH 7.2) is ished. Finally, the labeled HDAC7 protein is incubated for 120 minutes at 4°C. The labeled protein is pre-incubated with TMP195 for 30 minutes prior to application to the array in TMP195 competition experiments. After that, the microarrays are ished, dried, and imaged using a scanner.
|
|
| Cell Assay |
For five days, monocytes were differentiated into antigen-presenting cells in RPMI Medium 1640 supplemented with either 0.1% (v/v) DMSO or 300 nM TMP195. Other supplements included IL-4 (10 ng/ml), penicillin (100 U/ml), streptomycin (100 μg/ml), and GlutaMAX fetal bovine serum (10% v/v). After washing and incubating the cells in a 5 mM EDTA solution in Ca2+/Mg2+-free PBS, the cells were collected for flow cytometric analysis.
|
|
| Animal Protocol |
|
|
| References |
| Molecular Formula |
C23H19F3N4O3
|
|
|---|---|---|
| Molecular Weight |
456.42
|
|
| Exact Mass |
456.14
|
|
| Elemental Analysis |
C, 60.53; H, 4.20; F, 12.49; N, 12.28; O, 10.52
|
|
| CAS # |
1314891-22-9
|
|
| Related CAS # |
|
|
| PubChem CID |
67324851
|
|
| Appearance |
White to off-white solid powder
|
|
| Density |
1.3±0.1 g/cm3
|
|
| Index of Refraction |
1.546
|
|
| LogP |
5.57
|
|
| Hydrogen Bond Donor Count |
1
|
|
| Hydrogen Bond Acceptor Count |
9
|
|
| Rotatable Bond Count |
6
|
|
| Heavy Atom Count |
33
|
|
| Complexity |
672
|
|
| Defined Atom Stereocenter Count |
0
|
|
| SMILES |
FC(C1=NC(C2C([H])=C([H])C([H])=C(C=2[H])C(N([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C2=C([H])OC(C3C([H])=C([H])C([H])=C([H])C=3[H])=N2)=O)=NO1)(F)F
|
|
| InChi Key |
QTCSXAUJBQZZSN-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C23H19F3N4O3/c1-22(2,17-12-32-20(28-17)14-7-4-3-5-8-14)13-27-19(31)16-10-6-9-15(11-16)18-29-21(33-30-18)23(24,25)26/h3-12H,13H2,1-2H3,(H,27,31)
|
|
| Chemical Name |
N-[2-methyl-2-(2-phenyl-1,3-oxazol-4-yl)propyl]-3-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 3 mg/mL (6.57 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 30.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 3 mg/mL (6.57 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 30.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 3 mg/mL (6.57 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 5%DMSO+ Corn oil: 5.0mg/ml (10.95mM) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1910 mL | 10.9548 mL | 21.9096 mL | |
| 5 mM | 0.4382 mL | 2.1910 mL | 4.3819 mL | |
| 10 mM | 0.2191 mL | 1.0955 mL | 2.1910 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|---|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
